Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) 27.9% HIGHER; announced the publication of an article that reviews and discusses the company's seliciclib (CYC202 or R-roscovitine) product candidate, an orally available inhibitor of multiple cyclin-dependent kinases and its mechanism of action.
The peer-reviewed article, "Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs" was published in the online edition of Current Drug Targets.
Magal Security Systems (Nasdaq: MAGS) 22.2% HIGHER; the stock seems to be breaking out on technicals today.
Magal has been in the news...
Post new comment